IL273440A - Strengthening the effect of ATP release - Google Patents

Strengthening the effect of ATP release

Info

Publication number
IL273440A
IL273440A IL273440A IL27344020A IL273440A IL 273440 A IL273440 A IL 273440A IL 273440 A IL273440 A IL 273440A IL 27344020 A IL27344020 A IL 27344020A IL 273440 A IL273440 A IL 273440A
Authority
IL
Israel
Prior art keywords
potentiating
effect
atp release
atp
release
Prior art date
Application number
IL273440A
Other languages
English (en)
Hebrew (he)
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Publication of IL273440A publication Critical patent/IL273440A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL273440A 2017-11-15 2020-03-19 Strengthening the effect of ATP release IL273440A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762586224P 2017-11-15 2017-11-15
US201862686149P 2018-06-18 2018-06-18
US201862733175P 2018-09-19 2018-09-19
PCT/EP2018/081364 WO2019096900A1 (en) 2017-11-15 2018-11-15 Potentiating the effect of atp release

Publications (1)

Publication Number Publication Date
IL273440A true IL273440A (en) 2020-05-31

Family

ID=64332078

Family Applications (1)

Application Number Title Priority Date Filing Date
IL273440A IL273440A (en) 2017-11-15 2020-03-19 Strengthening the effect of ATP release

Country Status (11)

Country Link
US (1) US20190218304A1 (enExample)
EP (1) EP3710052A1 (enExample)
JP (1) JP7383609B2 (enExample)
KR (1) KR102781619B1 (enExample)
CN (1) CN111372606B (enExample)
AU (1) AU2018368541B2 (enExample)
BR (1) BR112020009655A8 (enExample)
CA (1) CA3075371A1 (enExample)
IL (1) IL273440A (enExample)
SG (1) SG11202002195YA (enExample)
WO (1) WO2019096900A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2238170T3 (en) 2008-01-31 2017-02-27 Inserm - Inst Nat De La Santé Et De La Rech Médicale ANTIBODIES AGAINST HUMAN CD39 AND ITS USE FOR INHIBITING ACTIVITY OF T-REGULATORY CELLS
MX2019010848A (es) 2017-03-16 2019-10-30 Innate Pharma Composiciones y procedimientos para el tratamiento del cancer.
US12226479B2 (en) 2017-05-11 2025-02-18 The General Hospital Corporation Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
SG10202111869SA (en) 2017-07-31 2021-11-29 Trishula Therapeutics Inc Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
EP3692068B1 (en) * 2017-10-06 2022-12-07 Innate Pharma Restoration of t cell activity via the cd39/cd73 axis
JP7368453B2 (ja) 2018-05-03 2023-10-24 シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド Ｐｄ－１およびｌａｇ－３に対する高親和性抗体ならびにそれらから作製された二重特異性結合タンパク質
JP7500442B2 (ja) 2018-06-18 2024-06-17 イナート・ファルマ・ソシエテ・アノニム 癌を処置するための組成物及び方法
CN110407941B (zh) * 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途
US12391756B2 (en) 2019-11-05 2025-08-19 Jacobio Pharmaceuticals Co., Ltd. Binding molecule specific for CD39 and use thereof
KR102856075B1 (ko) 2020-07-17 2025-09-04 삼성전자주식회사 비휘발성 메모리 장치 및 그 동작 방법
CN115975030B (zh) * 2021-09-30 2023-09-26 杭州邦顺制药有限公司 抗cd39抗体-药物偶联物及其用途
KR20240156633A (ko) 2022-03-03 2024-10-30 아르커스 바이오사이언시즈 인코포레이티드 항-cd39 항체 및 이의 용도
CN119013304A (zh) * 2022-03-04 2024-11-22 翠舒拉治疗股份有限公司 在胃癌中使用抗人cd39抗体、抗人pd-1抗体和化疗的组合
CN117903311B (zh) * 2024-03-20 2024-10-25 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
DK2238170T3 (en) 2008-01-31 2017-02-27 Inserm - Inst Nat De La Santé Et De La Rech Médicale ANTIBODIES AGAINST HUMAN CD39 AND ITS USE FOR INHIBITING ACTIVITY OF T-REGULATORY CELLS
RU2746804C2 (ru) * 2014-10-10 2021-04-21 Иннейт Фарма Блокада cd73
EP3215538A4 (en) * 2014-11-07 2018-07-04 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
CA3005986A1 (en) 2015-11-23 2017-06-01 Innate Pharma Cd39 vascular isoform targeting agents
EP3912681A1 (en) 2016-03-14 2021-11-24 Orega Biotech Anti-cd39 antibodies
MX2019010848A (es) * 2017-03-16 2019-10-30 Innate Pharma Composiciones y procedimientos para el tratamiento del cancer.
CN113754768B (zh) * 2018-03-14 2023-01-06 表面肿瘤学公司 结合cd39的抗体及其用途

Also Published As

Publication number Publication date
BR112020009655A8 (pt) 2023-03-21
JP2021502980A (ja) 2021-02-04
AU2018368541B2 (en) 2025-06-12
EP3710052A1 (en) 2020-09-23
US20190218304A1 (en) 2019-07-18
CN111372606B (zh) 2024-02-20
KR20200088811A (ko) 2020-07-23
SG11202002195YA (en) 2020-04-29
CA3075371A1 (en) 2019-05-23
KR102781619B1 (ko) 2025-03-14
WO2019096900A1 (en) 2019-05-23
BR112020009655A2 (pt) 2020-10-13
JP7383609B2 (ja) 2023-11-20
AU2018368541A1 (en) 2020-03-19
CN111372606A (zh) 2020-07-03

Similar Documents

Publication Publication Date Title
IL273440A (en) Strengthening the effect of ATP release
IL321844A (en) Menin–MLL interaction inhibitors
IL275482A (en) Asketamine for the treatment of depression
PL3512850T3 (pl) Inhibitory interakcji menina-mll
IL271290A (en) Dihydro-pyrrolo-pyridine derivatives
AU364417S (en) Back of the case
PL3177329T3 (pl) Układ do natychmiastowego uwalniania substancji aktywnych
GB2603420B (en) Synthesis of AEI and Cu-AEI zeolites
SMT202100551T1 (it) Derivati di sobetirome
PL3474822T3 (pl) Preparaty brincydofowiru
IL274627A (en) Solid forms of valbenazine
IL265628A (en) Solid state forms of valbenazine
GB201522764D0 (en) Formulations of phosphate derivatives
SI3652176T1 (sl) Substituirani ksantinski derivati
IL269034A (en) Combination of isoindolinone derivatives with SGI-110
GB2562645B (en) Self-locking coupler
IL273949A (en) Drug derivatives of modified triazole derivatives and their uses
IL254666A0 (en) Crystalline forms of Aldecalcitol
GB201718277D0 (en) Modified solid polymethylaluminoxane
AP2017009770A0 (en) The game of gendaball
TWM534080U (en) Structural improvement of box body
PT3319956T (pt) Derivados de oxopiridina substituída
GB201417646D0 (en) Formulations of phosphate derivatives
IL234250A0 (en) Derivatives of n - melamine Melamine as a disinfectant and biocide